Archives
-
Measuring Drug Responses in Cancer In Vitro
2026-08-15
Hannah Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating proliferative arrest from cell killing and considering their timing, the study provides a more precise framework for interpreting in vitro pharmacology and designing cancer research assays.
-
hiPSC Intestinal Organoids for Pharmacokinetic Studies
2026-08-14
Saito and colleagues developed an accessible direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be maintained, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated metabolic and transporter activities relevant to oral drug pharmacokinetics.
-
One-step TUNEL FITC Apoptosis Kit Guide
2026-08-14
The One-step TUNEL FITC Apoptosis Detection Kit uses FITC-labeled dUTP incorporation to visualize DNA strand breaks associated with apoptosis. SKU K1133 supports fluorescence microscopy and flow cytometry in tissue sections and cultured cells, but TUNEL signal should be interpreted with appropriate controls and orthogonal apoptosis measurements.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-08-13
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. By combining LIRP with AAV or engineered cell delivery, the authors demonstrate reversible, light-dependent regulation in obesity and retinal neovascular disease models, while also identifying the design principles and translational barriers relevant to regulated gene therapy.
-
HyperScript RT SuperMix for qPCR Workflow
2026-08-13
Turn limited or structurally challenging RNA into reproducible cDNA for gene expression analysis with a streamlined two-step qRT-PCR workflow. This guide translates the Pedalitin–NAFLD cell-model study into practical assay design, control selection, and troubleshooting decisions.
-
CD146+ Stem Cells Drive Brain Metastasis Angiogenesis
2026-08-12
This 2026 Theranostics study identifies CD146+ pericyte-like brain metastatic cancer stem cells as active regulators of tumor vascularization, not merely markers of a perivascular phenotype. Its central finding is that CD146 amplifies the VEGF/VEGFR2 axis at both the tumor and endothelial levels, suggesting that CD146 or upstream AXL signaling may overcome limitations of VEGF-neutralizing therapy.
-
ELAVL3/MYCN Feedback in Neuroendocrine Prostate Cancer
2026-08-12
The reference study identifies ELAVL3 as an RNA-binding driver of neuroendocrine prostate cancer and defines a positive feedback loop in which MYCN induces ELAVL3, while ELAVL3 stabilizes MYCN and RICTOR transcripts. By combining molecular, extracellular-vesicle, and mouse-model experiments, the work supports ELAVL3 inhibition as a strategy for limiting neuroendocrine differentiation and tumor progression.
-
Mitoxantrone: Mechanism, Resistance, and Workflows
2026-08-11
Mitoxantrone is a DNA-intercalating topoisomerase II inhibitor used as an anticancer research compound and apoptosis inducer in B-CLL cells. Its activity is influenced by ABCG2-mediated drug efflux, while experimental antiviral findings support investigation as an anti-orthopoxvirus agent rather than a clinical antiviral treatment.
-
Anisomycin: JNK Agonist Workflow for Apoptosis
2026-08-11
Anisomycin provides a practical way to trigger JNK pathway activation in apoptosis, stress-response, and cancer-cell assays. This workflow connects established cell-based applications with the reference study’s neuroligin-fragment mechanism while clearly separating validated evidence from exploratory neuroscience use.
-
Palonosetron in CINV: Evidence and Clinical Position
2026-08-10
This review evaluates palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for preventing radio- and chemotherapy-induced nausea and vomiting. Its main contribution is to connect distinctive pharmacology with improved control of delayed symptoms after moderately emetogenic chemotherapy, while identifying persistent evidence gaps in combination and multiple-day treatment settings.
-
From SERPINB5 Biology to qPCR Translation
2026-08-09
A translational framework for validating SERPINB5 biology in lung adenocarcinoma with specific, reproducible SYBR Green qPCR workflows.
-
USP36–Snail1 Axis in Ribotoxic Stress
2026-08-08
The reference study identifies a JNK–USP36–Snail1 surveillance pathway that allows solid tumor cells to maintain ribosome biogenesis and survive ribotoxic stress. Its findings explain why homoharringtonine is more effective in leukemia than in solid tumors and support combination strategies that inhibit this adaptive axis.
-
Ademetionine in Neurological Disorders: 1994 Review
2026-08-07
Bottiglieri, Hyland, and Reynolds presented Ademetionine, or S-adenosylmethionine (SAMe), as a biochemical link between one-carbon metabolism, neurotransmitter regulation, and neurological disease. Their review integrated mechanistic and early clinical evidence for antidepressant effects, possible cognitive benefit, and remyelination associated with methyl-donor treatment while emphasizing the preliminary nature of much of the evidence.
-
Thymoquinone: Multi-Pathway Modulator in Biomedical Research
2026-08-07
Explore the multifaceted role of thymoquinone as a bioactive research tool. This article uniquely analyzes its multi-pathway modulation—bridging cardioprotection, oncology, and inflammation—while providing expert assay guidance.
-
Fucoidan's Molecular Impact: Beyond Oncology into Antiviral
2026-08-06
Discover how Fucoidan, a potent sulfated α-L-Fucan from brown seaweed, advances not only cancer research but also offers new perspectives on antiviral mechanisms. This article uniquely explores cross-domain signaling pathways, integrating recent membrane fusion findings to inform both oncology and viral assays.